Novo Nordisk Reports Strong 2025 Sales Growth with Mixed Operating Profit Results
Novo Nordisk announced its full-year 2025 financial results, reporting sales of DKK 309.1 billion, a 6% increase in Danish kroner and 10% growth at constant exchange rates. Operating profit showed a mixed performance, declining 1% in local currency but rising 6% at constant exchange rates, impacted by transformation costs. The company highlighted strong demand for obesity treatments and expects competitive pricing pressures and regulatory decisions in 2026. Despite a stock price drop post-report, the results reflect robust volume growth and innovation.